Joshua Carter is a co-founder and the CEO of Helix BioStructures, a contract research organization serving the pharmaceutical industry in early-phase drug discovery. Since starting Helix Biostructures in 2017, Carter has leveraged the fast-paced, industrial capabilities of NSLS-II to perform x-ray crystallography experiments for his high volume of clients. Through Carter's work at NSLS-II, in addition to other services his company provides, Helix Biostructures has helped the pharmaceutical industry develop and improve therapies for a variety of diseases.